211 related articles for article (PubMed ID: 36860695)
1. An Unbiased Functional Genetics Screen Identifies Rare Activating ERBB4 Mutations.
Chakroborty D; Ojala VK; Knittle AM; Drexler J; Tamirat MZ; Ruzicka R; Bosch K; Woertl J; Schmittner S; Elo LL; Johnson MS; Kurppa KJ; Solca F; Elenius K
Cancer Res Commun; 2022 Jan; 2(1):10-27. PubMed ID: 36860695
[TBL] [Abstract][Full Text] [Related]
2. An unbiased
Chakroborty D; Kurppa KJ; Paatero I; Ojala VK; Koivu M; Tamirat MZ; Koivunen JP; Jänne PA; Johnson MS; Elo LL; Elenius K
J Biol Chem; 2019 Jun; 294(24):9377-9389. PubMed ID: 30952700
[TBL] [Abstract][Full Text] [Related]
3. Activating ERBB4 mutations in non-small cell lung cancer.
Kurppa KJ; Denessiouk K; Johnson MS; Elenius K
Oncogene; 2016 Mar; 35(10):1283-91. PubMed ID: 26050618
[TBL] [Abstract][Full Text] [Related]
4. ERBB4 mutation analysis: emerging molecular target for melanoma treatment.
Lau C; Killian KJ; Samuels Y; Rudloff U
Methods Mol Biol; 2014; 1102():461-80. PubMed ID: 24258993
[TBL] [Abstract][Full Text] [Related]
5. Somatic mutations of ErbB4: selective loss-of-function phenotype affecting signal transduction pathways in cancer.
Tvorogov D; Sundvall M; Kurppa K; Hollmén M; Repo S; Johnson MS; Elenius K
J Biol Chem; 2009 Feb; 284(9):5582-91. PubMed ID: 19098003
[TBL] [Abstract][Full Text] [Related]
6. Frequency, impact and a preclinical study of novel
Elster N; Toomey S; Fan Y; Cremona M; Morgan C; Weiner Gorzel K; Bhreathnach U; Milewska M; Murphy M; Madden S; Naidoo J; Fay J; Kay E; Carr A; Kennedy S; Furney S; Mezynski J; Breathhnach O; Morris P; Grogan L; Hill A; Kennedy S; Crown J; Gallagher W; Hennessy B; Eustace A
Ther Adv Med Oncol; 2018; 10():1758835918778297. PubMed ID: 30023006
[TBL] [Abstract][Full Text] [Related]
7. Afatinib against Esophageal or Head-and-Neck Squamous Cell Carcinoma: Significance of Activating Oncogenic HER4 Mutations in HNSCC.
Nakamura Y; Togashi Y; Nakahara H; Tomida S; Banno E; Terashima M; Hayashi H; de Velasco MA; Sakai K; Fujita Y; Okegawa T; Nutahara K; Hamada S; Nishio K
Mol Cancer Ther; 2016 Aug; 15(8):1988-97. PubMed ID: 27207775
[TBL] [Abstract][Full Text] [Related]
8. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
Roskoski R
Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458
[TBL] [Abstract][Full Text] [Related]
9. A growing family: adding mutated Erbb4 as a novel cancer target.
Rudloff U; Samuels Y
Cell Cycle; 2010 Apr; 9(8):1487-503. PubMed ID: 20404484
[TBL] [Abstract][Full Text] [Related]
10. ERBB4 promoter polymorphism is associated with poor distant disease-free survival in high-risk early breast cancer.
Kurppa KJ; Rokavec M; Sundvall M; Kellokumpu-Lehtinen PL; Joensuu H; Brauch H; Elenius K
PLoS One; 2014; 9(7):e102388. PubMed ID: 25036186
[TBL] [Abstract][Full Text] [Related]
11. The role of ERBB4 mutations in the prognosis of advanced non-small cell lung cancer treated with immune checkpoint inhibitors.
Hu X; Xu H; Xue Q; Wen R; Jiao W; Tian K
Mol Med; 2021 Oct; 27(1):126. PubMed ID: 34620079
[TBL] [Abstract][Full Text] [Related]
12. Receptor tyrosine kinase ERBB4 mediates acquired resistance to ERBB2 inhibitors in breast cancer cells.
Canfield K; Li J; Wilkins OM; Morrison MM; Ung M; Wells W; Williams CR; Liby KT; Vullhorst D; Buonanno A; Hu H; Schiff R; Cook RS; Kurokawa M
Cell Cycle; 2015; 14(4):648-55. PubMed ID: 25590338
[TBL] [Abstract][Full Text] [Related]
13. Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4.
Prickett TD; Agrawal NS; Wei X; Yates KE; Lin JC; Wunderlich JR; Cronin JC; Cruz P; Rosenberg SA; Samuels Y
Nat Genet; 2009 Oct; 41(10):1127-32. PubMed ID: 19718025
[TBL] [Abstract][Full Text] [Related]
14. Somatic mutations of the ERBB4 kinase domain in human cancers.
Soung YH; Lee JW; Kim SY; Wang YP; Jo KH; Moon SW; Park WS; Nam SW; Lee JY; Yoo NJ; Lee SH
Int J Cancer; 2006 Mar; 118(6):1426-9. PubMed ID: 16187281
[TBL] [Abstract][Full Text] [Related]
15. ErbB4-mediated regulation of vasculogenic mimicry capability in breast cancer cells.
Kawahara R; Simizu S
Cancer Sci; 2022 Mar; 113(3):950-959. PubMed ID: 34971015
[TBL] [Abstract][Full Text] [Related]
16. The Q43L mutant of neuregulin 2β is a pan-ErbB receptor antagonist.
Wilson KJ; Mill CP; Gallo RM; Cameron EM; VanBrocklin H; Settleman J; Riese DJ
Biochem J; 2012 Apr; 443(1):133-44. PubMed ID: 22216880
[TBL] [Abstract][Full Text] [Related]
17. Trans-activating mutations of the pseudokinase ERBB3.
Koivu MKA; Chakroborty D; Airenne TT; Johnson MS; Kurppa KJ; Elenius K
Oncogene; 2024 May; ():. PubMed ID: 38806620
[TBL] [Abstract][Full Text] [Related]
18. The receptor tyrosine kinase ERBB4 is expressed in skin keratinocytes and influences epidermal proliferation.
Hoesl C; Röhrl JM; Schneider MR; Dahlhoff M
Biochim Biophys Acta Gen Subj; 2018 Apr; 1862(4):958-966. PubMed ID: 29410073
[TBL] [Abstract][Full Text] [Related]
19. miR-193a-3p functions as a tumor suppressor in lung cancer by down-regulating ERBB4.
Liang H; Liu M; Yan X; Zhou Y; Wang W; Wang X; Fu Z; Wang N; Zhang S; Wang Y; Zen K; Zhang CY; Hou D; Li J; Chen X
J Biol Chem; 2015 Jan; 290(2):926-40. PubMed ID: 25391651
[TBL] [Abstract][Full Text] [Related]
20. Potential therapeutic efficiency of pan-ERBB inhibitors for canine glioma.
Noguchi S; Yasumura M
Vet Res Commun; 2023 Dec; 47(4):2207-2213. PubMed ID: 36991174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
